CJC-1295/Ipamorelin Combination: Research Overview and Background

The combination of CJC-1295 and Ipamorelin is among the most frequently discussed peptide stacks in GH research. Both peptides stimulate growth hormone release, but through different receptor systems. This complementary mechanism is why the combination has been studied in research settings.

This article summarises the available data: mechanisms of action, pharmacokinetic differences, synergy data and the safety profiles of both peptides.

CJC-1295/Ipamorelingrowth

2-in-1 growth hormone blend: CJC-1295 + Ipamorelin in one vial. Stimulates natural GH release through two different pathways for amplified, more physiological growth hormone pulses. The gold standard GH research combination.

CJC-1295: GHRH Analogue with Extended Duration

CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH). It consists of the first 29 amino acids of natural GHRH with four amino acid substitutions that confer resistance to degradation by dipeptidyl peptidase-4 (DPP-4).

With and Without DAC

A key practical distinction concerns the variant:

• CJC-1295 with DAC (Drug Affinity Complex): The DAC component binds to albumin in the blood, extending the half-life to approximately 6-8 days. A single injection can elevate GH levels for several days.
• CJC-1295 without DAC (also called Mod GRF 1-29): Half-life of approximately 30 minutes. Requires multiple daily doses but produces a more pulsatile release pattern.

Clinical Data

Teichman et al. (2006) published the key clinical study on CJC-1295 with DAC in the Journal of Clinical Endocrinology & Metabolism. In this randomised, placebo-controlled, double-blind study of healthy adults (ages 21-61), a single subcutaneous injection produced:

• Dose-dependent GH increases of 2- to 10-fold for 6 days or longer
• IGF-1 increases of 1.5- to 3-fold for 9-11 days
• Estimated half-life: 5.8-8.1 days
• Evidence of a cumulative effect with repeated dosing

The authors described the administration as safe and well tolerated, particularly at doses of 30 or 60 mcg/kg. Reported side effects were mild injection site reactions.

Ipamorelin: Selective Ghrelin Receptor Agonist

Ipamorelin is a pentapeptide that acts on the ghrelin receptor (GHS-R1a) of somatotroph cells in the pituitary gland. It belongs to the Growth Hormone Releasing Peptide (GHRP) class but differs from older members through a significantly more selective profile.

Selectivity as a Distinguishing Feature

Raun et al. (1998) described Ipamorelin in the European Journal of Endocrinology as the "first selective growth hormone secretagogue". The key observation:

• Ipamorelin released GH without significantly raising ACTH or cortisol above GHRH control levels
• Even at doses exceeding 200-fold the ED50 for GH release, cortisol levels remained stable
• No significant effect on FSH, LH, prolactin or TSH

For comparison: GHRP-6 and GHRP-2 produce measurable increases in ACTH and cortisol at equivalent GH-stimulating doses. These side effects limit their use in certain research contexts.

The Synergy: GHRH + GHRP

Combining a GHRH analogue with a GHRP is not a new concept. Bowers et al. described as early as 1991 in Endocrinology that GHRP stimulates GH release through an independent, complementary mechanism - separate from the GHRH receptor and independent of opiate receptors.

Two Separate Signalling Pathways

The synergistic effect arises from simultaneous activation of two different receptor systems:

1. GHRH receptor (activated by CJC-1295): Stimulates the cAMP signalling cascade in somatotroph cells
2. GHS-R1a (activated by Ipamorelin): Stimulates the phospholipase C cascade and intracellular calcium release

These separate intracellular signalling pathways converge at GH secretion, producing a stronger response together than either pathway alone.

Quantitative Data

Veldhuis et al. (2009) systematically examined the determinants of GHRH-GHRP synergy in the American Journal of Physiology. The key findings:

• Co-administration produced 2- to 4-fold higher GH AUC (area under the curve) compared to either compound alone
• The effect was additive to synergistic depending on timing
• IGF-1 elevations were approximately 20-30% higher than with single administration

These data relate to the general GHRH+GHRP combination. Specific clinical studies on the exact CJC-1295 plus Ipamorelin combination are limited. The transferability derives from shared receptor pharmacology.

DAC or No DAC: What Matters for Research?

The choice of CJC-1295 variant has direct consequences for research design:

Parameter	CJC-1295 with DAC	CJC-1295 without DAC (Mod GRF 1-29)
Half-life	6-8 days	approx. 30 minutes
GH release pattern	Continuously elevated baseline	Pulsatile
Dosing frequency	1-2x per week	2-3x daily
Physiological similarity	Less physiological	Closer to natural pattern

The DAC variant produces sustained GH elevation that does not match the natural pulsatile pattern. For research questions where physiological pulsatility is relevant, the variant without DAC is often preferred.

However, the study by Ionescu & Bhatt (2006) showed that pulsatile GH secretion is maintained even under continuous CJC-1295 DAC stimulation - endogenous somatostatin regulation appears to remain functional.

Safety Profile

CJC-1295

Data from Teichman et al. (2006) showed no serious adverse events in the studied dose ranges (30-60 mcg/kg). Reported mild side effects included:

• Injection site reactions (redness, swelling)
• Transient flushing
• Mild water retention

Ipamorelin

Ipamorelin is described in the literature as well tolerated. The most commonly reported mild effects are:

• Headaches
• Transient fatigue
• Mild nausea

The absence of significant cortisol and prolactin increases represents a safety advantage over other GHRPs.

Summary of Research

The CJC-1295/Ipamorelin combination utilises the complementary receptor pharmacology of GHRH and GHRP signalling pathways. The data support the following key points:

• CJC-1295 extends GHRH receptor activation and increased GH and IGF-1 in a dose-dependent manner in clinical studies (Teichman et al., 2006)
• Ipamorelin is the most selective known GHRP with minimal impact on cortisol and prolactin (Raun et al., 1998)
• GHRH+GHRP combinations produce synergistic GH responses with 2-4-fold higher AUC than individual compounds (Veldhuis et al., 2009)
• Both peptides showed a favourable safety profile in short-term studies

Research on this combination remains active, but long-term data and large randomised trials are lacking. For the current state of knowledge, the cited publications provide a solid foundation.

Frequently Asked Questions

Order CJC-1295/Ipamorelin

CJC-1295/Ipamorelingrowth

2-in-1 growth hormone blend: CJC-1295 + Ipamorelin in one vial. Stimulates natural GH release through two different pathways for amplified, more physiological growth hormone pulses. The gold standard GH research combination.

References

1. Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3), 799-805.
2. Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 139(5), 552-561.
3. Bowers CY et al. (1991). On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology, 128(4), 2027-2035.
4. Veldhuis JD et al. (2009). Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab, 296(5), E1085-E1092.
5. Ionescu M, Bhatt DL (2006). Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab, 91(12), 4792-4797.